After Aktis's $318m flotation Eikon is a bigger proposition.

AKY-1189 could be used in Padcev-relapsed patients, and in cancers beyond bladder.

Aktis scores a plenary, as do Tyra’s FGFR3 inhibitor and Arcus’s HIF-2α contender.